logo
Accenture's Q3 GenAI Bookings of $1.5 billion Far Ahead of Indian IT Services Firms

Accenture's Q3 GenAI Bookings of $1.5 billion Far Ahead of Indian IT Services Firms

Entrepreneur26-06-2025
Accenture increased its data and AI workforce to approximately 75,000, continuing progress against our goal of 80,000 by the end of FY26.
You're reading Entrepreneur India, an international franchise of Entrepreneur Media.
Dublin-based IT major Accenture has been leading on the generative AI (GenAI) front with Q3 bookings of USD 1.5 billion and over USD 700 million of revenues. This translates to a Q3 year-to-date total GenAI bookings of USD 4.1 billion and revenue of USD 1.8 billion.
Accenture's GenAI numbers are the highest in industry and far ahead of all Indian IT services companies. Among Indian companies, so far only Tata Consultancy Services (TCS) has declared revenue from this emerging technology.
Last fiscal, TCS management said during its Q1 earnings that it has about USD 1.5 billion worth of AI and Gen AI projects in the pipeline as of the first quarter ended June 30.
TCS had clocked USD 900 million worth of AI and Gen AI projects as of the fourth quarter ended March 31, 2024. K. Krithivasan, CEO and MD, TCS, said during the Q1 earnings, "We are currently executing about 270 AI projects across TCS."
"GenAI has been a catalyst for reinvention because the power of GenAI has created the opportunity to meet challenges in new ways and is creating new opportunities to achieve even better results than any single technology in the internet era. And yet Gen AI alone is just a tool. The work needed to use Gen AI to create value at scale is substantial," Julie Sweet, CEO, Accenture said in a post-earnings call.
"We increased our data and AI workforce to approximately 75,000, continuing progress against our goal of 80,000 by the end of FY26," Sweet said.
Accenture, which follows a September-August financial year, was first among IT companies to declare its quarterly earnings. It has increased the upper end of the annual revenue growth guidance between 6-7 per cent, compared with its prior forecast of 5-7 per cent.
It reported revenues of USD 17.7 billion, an increase of 8 per cent in US dollars and 7 per cent in local currency for the March-May quarter. Its operating margin stood at 16.8 per cent, an increase of 80 basis points, and an increase of 40 basis points compared to adjusted operating margin.
Accenture's earnings, seen as a barometer for the Indian IT services sector, seems to have failed to cheer the Indian markets with tech stocks falling about 3 per cent post the results. However, CLSA has retained its positive stance on the Indian IT sector. The brokerage also cited the strength in Accenture's BFSI segment, something similar that has been observed in the commentary of India's IT companies as well.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Oculis Holding AG (OCS) Reports Q2 Loss, Beats Revenue Estimates
Oculis Holding AG (OCS) Reports Q2 Loss, Beats Revenue Estimates

Yahoo

time41 minutes ago

  • Yahoo

Oculis Holding AG (OCS) Reports Q2 Loss, Beats Revenue Estimates

Oculis Holding AG (OCS) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to a loss of $0.56 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -11.32%. A quarter ago, it was expected that this company would post a loss of $0.51 per share when it actually produced a loss of $0.77, delivering a surprise of -50.98%. Over the last four quarters, the company has not been able to surpass consensus EPS estimates. Oculis Holding AG, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $0.32 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 28.54%. This compares to year-ago revenues of $0.27 million. The company has topped consensus revenue estimates two times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Oculis Holding AG shares have added about 3.2% since the beginning of the year versus the S&P 500's gain of 8.7%. What's Next for Oculis Holding AG? While Oculis Holding AG has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Oculis Holding AG was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.54 on $0.25 million in revenues for the coming quarter and -$2.44 on $0.82 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 42% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Phibro Animal Health (PAHC), another stock in the broader Zacks Medical sector, has yet to report results for the quarter ended June 2025. The results are expected to be released on August 27. This maker of animal health products and nutritional supplements is expected to post quarterly earnings of $0.52 per share in its upcoming report, which represents a year-over-year change of +26.8%. The consensus EPS estimate for the quarter has been revised 1% higher over the last 30 days to the current level. Phibro Animal Health's revenues are expected to be $361.15 million, up 32.2% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Oculis Holding AG (OCS) : Free Stock Analysis Report Phibro Animal Health Corporation (PAHC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store